| CAS NO: | 172997-92-1 |
| 包装 | 价格(元) |
| 1mg | 电议 |
| 5mg | 电议 |
| 25mg | 电议 |
| Cas No. | 172997-92-1 |
| 化学名 | (S,S,S,1Z,1'Z,2S,2'S)-N'1,N''1'-((R,S,6S,6'S,7Z,7'Z,9S,9'S,10Z,10'Z,12S,12'S,13Z,13'Z,15S,15'S,16Z,16'Z,18R,18'R,19Z,19'Z,21S,21'S)-18,18'-(disulfanediylbis(methylene))bis(1-amino-12-(3-guanidinopropyl)-8,11,14,17,20-pentahydroxy-6-((Z)-hydroxy(((S)-1-hyd |
| Canonical SMILES | CCC[C@@](/N=C(O)/[C@](/N=C(O)/[C@](/N=C(O)/[C@](/N=C(O)/[C@](/N=C(O)/[C@](/N=C(O)/[C@](/N=C(O)/[C@](N)([H])CC1=CC=C(O)C=C1)([H])[C@@](CC)([H])C)([H])CC(O)=N)([H])CC(C)C)([H])CSSC[C@@](/N=C(O)/[C@](/N=C(O)/[C@](/N=C(O)/[C@](/N=C(O)/[C@](N)([H])CC2=CC=C(O)C |
| 分子式 | C116H186N36O28S2 |
| 分子量 | 2597.07 |
| 溶解度 | ≥ 260.4 mg/mL in DMSO with ultrasonic,<12.99 mg/mL in Water,<12.99 mg/mL in EtOH |
| 储存条件 | Desiccate at -20°C |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
| Shipping Condition | Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request |
| 产品描述 | IC50: 0.5 nM for Y5 The actions of neuropeptide Y (NPY) are mediated by at least six G-protein coupled receptors denoted as Y1, Y2, Y3, Y4, Y5, and y6. Investigations using receptor selective ligands and receptor knock-out mice show that NPY effects on feeding are mediated by both Y1 and Y5 receptors. BWX 46 is a Y5 receptor selective agonist. In vitro: BWX 46 selectively bound Y5 receptors, and inhibited cAMP synthesis by Y5 cells with potencies comparable to that of NPY. In addition, BWX 46 (10 μM) exhibited no significant effect on the cAMP synthesis by Y1, Y2, and Y4 cells. Thus, BWX 46 constitutes the lowest molecular weight Y5 selective agonist reported to date [1]. In vivo: Intrahypothalamic-injection of 30 and 40 μg of BWX 46 stimulated the food intake by rats in a gradual manner, reaching maximal level 8 h after injection. This response was similar to that exhibited by other Y5 selective agonists, but differed from that of NPY, which exhibited a rapider orexigenic stimulus within 1 h [1]. Clinical trial: Up to now, BWX 46 is still in the preclinical development stage. Reference: |
m.cnreagent.com